Übersicht
Veränderung der Aktienkurses
24h
Aktuell
Min
48.76
Max
48.76
Empfehlungen | Buy |
|---|---|
12-Monats-Prognose | +35.05% upside |
Nächstes Ergebnis | 3. Nov. 2026 |
|---|
Nachrichtenstimmung
By Acuity
16%
84%
15 / 339 Ranking in Healthcare
Rigel Pharmaceuticals Inc Chart
Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.
Ähnliche Nachrichten
23. Sept. 2026, 20:07 UTC
Rigel Pharmaceuticals Inc shares fell sharply amid a declining broader market, reaching a low of nearly 3.75% below Tuesday's close before a slight recovery.
Lesen
18. Sept. 2026, 20:02 UTC
Rigel Pharmaceuticals Inc is advancing today with unusually high trading activity, breaking from a recent trend of higher daily closes since Thursday.
Lesen
15. Sept. 2026, 20:02 UTC
Rigel Pharmaceuticals is trading lower as the NY Empire State Manufacturing Index fell sharply, raising concerns about economic contraction in New York's manufacturing sector.
Lesen
11. Sept. 2026, 19:46 UTC
Rigel Pharmaceuticals is higher today, influenced by CPI data and speculation about potential Federal Reserve interest rate hikes. The stock remains near its one-month trading range.
Lesen
10. Sept. 2026, 23:21 UTC
Rigel Pharmaceuticals Inc is rising in after-market trading, reversing a three-session decline. No specific news was identified to explain this price action.
Lesen
8. Sept. 2026, 20:07 UTC
Rigel Pharmaceuticals Inc shares are lower today, continuing a decline since Friday. The stock saw notable volatility but remains above its 20-day moving average.
Lesen
1. Sept. 2026, 20:08 UTC
Rigel Pharmaceuticals Inc shares are higher today, reflecting strong market performance and robust momentum above the 20-day moving average. No specific news was identified.
Lesen
31. Aug. 2026, 20:07 UTC
Rigel Pharmaceuticals is lower today as the market reacts to comments from Warsh at the Jackson Hole Economic Symposium regarding elevated inflation and potential rate hikes.
Lesen
25. Aug. 2026, 20:07 UTC
Rigel Pharmaceuticals shares are advancing, supported by easing Treasury yields and lower oil prices, despite pulling back from earlier session highs.
Lesen
24. Aug. 2026, 19:56 UTC
Rigel Pharmaceuticals Inc shares are lower today, with no specific news identified for the decline. The stock remains above its 20-day moving average.
Lesen
21. Aug. 2026, 19:36 UTC
Rigel Pharmaceuticals Inc is trading higher, despite pulling back from an earlier session peak. The stock remains above its 20-day moving average.
Lesen
20. Aug. 2026, 20:06 UTC
Rigel Pharmaceuticals Inc. shares are lower today, continuing a decline since Wednesday amid broader market pressures, though no specific news has been identified.
Lesen
19. Aug. 2026, 20:02 UTC
Rigel Pharmaceuticals Inc is trading higher amid strong market activity and high volume, reflecting increased investor interest since Tuesday's close.
Lesen
18. Aug. 2026, 22:01 UTC
Rigel Pharmaceuticals shares declined in after-market trading, dropping significantly amid broader market pressures from rising bond yields and inflation concerns.
Lesen
17. Aug. 2026, 20:06 UTC
Rigel Pharmaceuticals Inc. shares declined despite mixed analyst ratings updates. Piper Sandler raised its price target to $49, while H.C. Wainwright set it at $85.
Lesen
14. Aug. 2026, 20:06 UTC
HC Wainwright raised Rigel Pharmaceuticals' price target to $85, boosting investor sentiment. Shares are trading higher since Thursday's close amid mixed market conditions.
Lesen
13. Aug. 2026, 19:16 UTC
Rigel Pharmaceuticals shares decline following the launch of its breast cancer drug Veppanu, priced at $29,400 per month, amid safety concerns.
Lesen
11. Aug. 2026, 20:06 UTC
Rigel Pharmaceuticals Inc shares are higher in Tuesday's session, continuing gains from previous days amid routine fluctuations and no specific news driving the movement.
Lesen
7. Aug. 2026, 19:26 UTC
Rigel Pharmaceuticals reported EPS of $0.88, exceeding estimates. Revenue of $78.70 million also surpassed expectations, though analysts have mixed ratings on the stock.
Lesen
6. Aug. 2026, 20:06 UTC
Rigel Pharmaceuticals shares lower as the company in-licenses Veppanu for breast cancer treatment, projecting 2026 revenues of $285 million to $295 million.
Lesen
5. Aug. 2026, 20:02 UTC
Rigel Pharmaceuticals shares rise as the company reports Q2 EPS of $0.88, exceeding estimates, and raises full-year sales guidance to $285 million-$295 million.
Lesen
4. Aug. 2026, 23:01 UTC
Rigel Pharmaceuticals shares higher after reporting Q2 earnings of $0.88 and raising full-year sales guidance to $285 million to $295 million.
Lesen
3. Aug. 2026, 19:26 UTC
Rigel Pharmaceuticals Inc. is higher today, aligning with market trends as the S&P 500 and Nasdaq see gains amid improved investor sentiment.
Lesen
31. Juli 2026, 19:41 UTC
Rigel Pharmaceuticals is lower today amid significant downward pressure in the Biotechnology sub-sector, despite a slight recovery from session lows.
Lesen
30. Juli 2026, 19:29 UTC
Rigel Pharmaceuticals Inc shares are lower today amid unusual volatility, reaching a session low earlier after peaking shortly after the market opened.
Lesen
29. Juli 2026, 19:47 UTC
Rigel Pharmaceuticals Inc. is trading higher Wednesday, pulling back from earlier session highs amid mixed performance across major U.S. indices ahead of the Fed's decision.
Lesen
28. Juli 2026, 19:56 UTC
Rigel Pharmaceuticals shares are higher today as the company announced a conference call for its second quarter 2026 financial results on August 4.
Lesen
27. Juli 2026, 16:16 UTC
Rigel Pharmaceuticals is higher during Monday's session, rebounding after six days of declines. The stock remains up since Friday's close amid broader market dynamics.
Lesen
24. Juli 2026, 20:01 UTC
Rigel Pharmaceuticals Inc shares are higher today, recovering from earlier dips amid increased trading volume and broader market gains despite no specific news identified.
Lesen
22. Juli 2026, 20:06 UTC
Rigel Pharmaceuticals Inc shares are lower Wednesday amid ongoing market uncertainty ahead of the Federal Reserve meeting, with no specific news driving the decline.
Lesen
Peer-Vergleich
Kursveränderung
Rigel Pharmaceuticals Inc Prognose
Kursziel
By TipRanks
12-Monats-Prognose
Durchschnitt 65 USD 35.05%
Hoch 85 USD
Tief 43 USD
Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Rigel Pharmaceuticals Inc – Dist angeboten haben.
Rating-Konsens
By TipRanks
Buy
4 ratings
2
Buy
2
Halten
0
Sell
Basierend auf 4 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Rigel Pharmaceuticals Inc – Dist abgegeben haben.
Stimmung
By Acuity
Nachrichtenstimmung
Sehr starke bullische Evidenz
Volatilität
Unterdurchschnittlich
Nachrichtenvolumen (RCV)
Überdurchschnittlich
Finanzen
$